A dual drug regimen synergistically blocks human parainfluenza virus infection

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Bailly, Benjamin ^a,b   Dirr, Larissa ^a   El Deeb, Ibrahim M ^a   Altmeyer, Ralf ^b,c   Guillon, Patrice ^a   Von Itzstein, Mark ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b INSTITUTE PASTEUR OF SHANGHAI   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HN PROTEIN; PROTEIN BINDING; SURAMIN; VIRAL PROTEIN; ZANAMIVIR;

ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL LINE; CYTOLOGY; DRUG EFFECTS; DRUG POTENTIATION; EPITHELIUM CELL; HOST PATHOGEN INTERACTION; HUMAN PARAINFLUENZA VIRUS 3; KIDNEY; KINETICS; METABOLISM; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSIOLOGY; RHESUS MONKEY; VIROLOGY; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; CELL LINE; DRUG SYNERGISM; EPITHELIAL CELLS; HN PROTEIN; HOST-PATHOGEN INTERACTIONS; KIDNEY; KINETICS; MACACA MULATTA; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR DYNAMICS SIMULATION; PARAINFLUENZA VIRUS 3, HUMAN; PROTEIN BINDING; SURAMIN; VIRAL PROTEINS; VIRUS REPLICATION; ZANAMIVIR;

EID: 84963690535     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24138     Document Type: Article

References (54)

1. Moscona, A. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J. Clin. Invest. 115, 1688-1698 (2005).
2. Hall, C. B. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 344, 1917-1928 (2001).
3. Schmidt, A. C. et al. Progress in the development of human parainfluenza virus vaccines. Expert Rev. Respir. Med. 5, 515-526 (2011).
4. Cunha, B. A., Corbett, M., Mickail, N. Human parainfluenza virus type 3 (HPIV 3) viral community-acquired pneumonia (CAP) mimicking swine influenza (H1N1) during the swine flu pandemic. Heart Lung 40, 76-80 (2011).
5. Johnstone, J., Majumdar, S. R., Fox, J. D., Marrie, T. J. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 134, 1141-1148 (2008).
6. Zambon, M., Bull, T., Sadler, C. J., Goldman, J. M., Ward, K. N. Molecular epidemiology of two consecutive outbreaks of parainfluenza 3 in a bone marrow transplant unit. J. Clin. Microbiol. 36, 2289-2293 (1998).
7. Suzuki, T. et al. Receptor specificities of human respiroviruses. J. Virol. 75, 4604-4613 (2001).
8. Zhang, L. et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J. Virol. 79, 1113-1124 (2005).
9. Huberman, K., Peluso, R. W., Moscona, A. Hemagglutinin-neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle. Virology 214, 294-300 (1995).
10. Porotto, M., Palmer, S. G., Palermo, L. M., Moscona, A. Mechanism of Fusion Triggering by Human Parainfluenza Virus Type III COMMUNICATION BETWEEN VIRAL GLYCOPROTEINS DURING ENTRY. J. Biol. Chem. 287, 778-793 (2012).
11. Palermo, L. M. et al. Human parainfluenza virus infection of the airway epithelium: viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity. J. Virol. 83, 6900-6908 (2009).
12. Porotto, M. et al. Regulation of Paramyxovirus Fusion Activation: the Hemagglutinin-Neuraminidase Protein Stabilizes the Fusion Protein in a Pretriggered State. J. Virol. 86, 12838-12848 (2012).
13. Porotto, M., Murrell, M., Greengard, O., Doctor, L., Moscona, A. Influence of the human parainfluenza virus 3 attachment protein's neuraminidase activity on its capacity to activate the fusion protein. J. Virol. 79, 2383-2392 (2005).
14. Porotto, M., Murrell, M., Greengard, O., Moscona, A. Triggering of human parainfluenza virus 3 fusion protein (F) by the hemagglutinin-neuraminidase (HN) protein: an HN mutation diminishes the rate of F activation and fusion. J. Virol. 77, 3647-3654 (2003).
15. Porotto, M. et al. Paramyxovirus receptor-binding molecules: engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site. J. Virol. 80, 1204-1213 (2006).
16. Tindal, D. J. et al. Synthesis and evaluation of 4-O-alkylated 2-deoxy-2,3-didehydro-N-acetylneuraminic acid derivatives as inhibitors of human parainfluenza virus type-3 sialidase activity. Bioorg. Med. Chem. Lett. 17, 1655-1658 (2007).
17. Watanabe, M. et al. Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice. Antimicrob. Agents Chemother. 53, 3942-3951 (2009).
18. Merz, D. C., Prehm, P., Scheid, A., Choppin, P. W. Inhibition of the neuraminidase of paramyxoviruses by halide ions: a possible means of modulating the two activities of the HN protein. Virology 112, 296-305 (1981).
19. Guillon, P. et al. Structure-guided discovery of potent and dual-acting human parainfluenza virus haemagglutinin-neuraminidase inhibitors. Nat. Commun. 5, 5268 (2014).
20. Taylor, G. Sialidases: structures, biological significance and therapeutic potential. Curr. Opin. Struct. Biol. 6, 830-837 (1996).
21. Greengard, O., Poltoratskaia, N., Leikina, E., Zimmerberg, J., Moscona, A. The Anti-Influenza Virus Agent 4-GU-DANA (Zanamivir) Inhibits Cell Fusion Mediated by Human Parainfluenza Virus and Influenza Virus HA. J. Virol. 74, 11108-11114 (2000).
22. Porotto, M., Greengard, O., Poltoratskaia, N., Horga, M. A., Moscona, A. Human parainfluenza virus type 3 HN-receptor interaction: effect of 4-guanidino-Neu5Ac2en on a neuraminidase-deficient variant. J. Virol. 75, 7481-7488 (2001).
23. Alymova, I. V. et al. Efficacy of the Novel Parainfluenza Virus Hemagglutinin-Neuraminidase Inhibitor BCX 2798 in Mice-Further Evaluation. Antivir. Ther. 14, 891-898 (2009).
24. Alymova, I. V. et al. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. Antimicrob. Agents Chemother. 48, 1495-1502 (2004).
25. Winger, M., von Itzstein, M. Exposing the flexibility of human parainfluenza virus hemagglutinin-neuraminidase. J. Am. Chem. Soc. 134, 18447-18452 (2012).
26. Dirr, L. et al. The catalytic mechanism of human parainfluenza virus type 3 haemagglutinin-neuraminidase revealed. Angew. Chem. Int. Ed. Engl. 54, 2936-2940 (2015).
27. Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. World Health Organ. Tech. Rep. Ser. 881, I-VI, 1-114 (1998).
28. Simarro, P. P., Diarra, A., Ruiz Postigo, J. A., Franco, J. R., Jannin, J. G. The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward. Plos Negl. Trop. Dis. 5, e1007 (2011).
29. Yorke, W. THE TREATMENT OF KALA-AZAR BY 'BAYER 205'. Br. Med. J 1, 370 (1923).
30. Zhang, Chung & Oldenburg, A. Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen 4, 67-73 (1999).
31. Mendla, K., Cantz, M. Specificity studies on the oligosaccharide neuraminidase of human fibroblasts. Biochem. J 218, 625-628 (1984).
32. Schneider-Jakob, H. R., Cantz, M. Lysosomal and plasma membrane ganglioside GM3 sialidases of cultured human fibroblasts. Differentiation by detergents and inhibitors. Biol. Chem. 372, 443-450 (1991).
33. Oehler, C., Kopitz, J., Cantz, M. Substrate specificity and inhibitor studies of a membrane-bound ganglioside sialidase isolated from human brain tissue. Biol. Chem. 383, 1735-1742 (2002).
34. Chou, T. C., Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55 (1984).
35. Chou, T.-C., Talalay, P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci. 4, 450-454 (1983).
36. Chou, T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681 (2006).
37. Haselhorst, T. et al. Avian influenza H5-containing virus-like particles (VLPs): host-cell receptor specificity by STD NMR spectroscopy. Angew. Chem. Int. Ed. Engl. 47, 1910-1912 (2008).
38. Lawrence, M. C. et al. Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III. J. Mol. Biol. 335, 1343-1357 (2004).
39. Porotto, M. et al. Spring-loaded model revisited: paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein. J. Virol. 85, 12867-12880 (2011).
40. Porotto, M. et al. Inhibition of Parainfluenza Virus Type 3 and Newcastle Disease Virus Hemagglutinin-Neuraminidase Receptor Binding: Effect of Receptor Avidity and Steric Hindrance at the Inhibitor Binding Sites. J. Virol. 78, 13911-13919 (2004).
41. Krishnan, V. V. Ligand Screening by Saturation-Transfer Difference (STD) NMR Spectroscopy. Current Analytical Chemistry 1, 307-320 (2005).
42. Ren, P. et al. The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection-suramin inhibits EV71 infection in vitro and in vivo. Emerg. Microbes Infect. 3, e62 (2014).
43. von Itzstein, M., Wu, W. Y., Jin, B. The synthesis of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: a potent influenza virus sialidase inhibitor. Carbohydr. Res. 259, 301-305 (1994).
44. Thompson, S. D., Laver, W. G., Murti, K. G., Portner, A. Isolation of a biologically active soluble form of the hemagglutininneuraminidase protein of Sendai virus. J. Virol. 62, 4653-4660 (1988).
45. Potier, M., Mameli, L., Bélisle, M., Dallaire, L., Melançon, S. B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal. Biochem. 94, 287-296 (1979).
46. Suzuki, T. et al. Inhibition of human parainfluenza virus type 1 sialidase by analogs of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid. Glycoconj. J. 18, 331-337 (2001).
47. Holzer, C. T. et al. Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-Nacetylneuraminic acid modified at the C-4 position. Glycoconj. J. 10, 40-44 (1993).
48. Ryu, Y. B. et al. Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg. Med. Chem. 17, 2744-2750 (2009).
49. Nguyen, P. H. et al. Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg. Med. Chem. 18, 3335-3344 (2010).
50. Mishin, V. P. et al. N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site. J. Virol. 84, 3094-3100 (2010).
51. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676-682 (2012).
52. Chou, T. C. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J. Theor. Biol. 59, 253-276 (1976).
53. Trott, O., Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455-461 (2010).
54. Schüttelkopf, A. W., van Aalten, D. M. F. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr 60, 1355-1363 (2004).